Investor Updates

20. November 2009
European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting ... more

20. November 2009
ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
Roche announced today that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) successfully met its primary endpoint in ... more

18. November 2009
US FDA issues complete response letter for Rituxan/MabThera for chronic lymphocytic leukaemia
Roche announced today that the US Food and Drug Administration (FDA) issued a complete response to Genentech, a wholly-owned ... more

18. November 2009
Invitation to Roche investor science event from SABCS 2009
We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented ... more

18. November 2009
Roche announces start of new atherosclerosis study (dal-PLAQUE 2) for dalcetrapib
Roche today presented new preclinical data further supporting the differentiation of its novel cholesteryl ester transfer ... more

17. November 2009
Applications to allow Avastin to be combined with commonly used chemotherapies in advanced breast cancer submitted to FDA
Roche announced today that Genentech, a wholly-owned member of the Roche Group, has submitted two supplemental Biologics License ... more

16. November 2009
FDA Grants Emergency Use Authorization to Roche's Assay for 2009 H1N1 Influenza Virus
Roche announced today that it's RealTime ready Influenza A/H1N1 Detection Set for the 2009 H1N1 influenza virus has received ... more

10. November 2009
Roche reports positive Phase II results with potential first-in-class treatment for the negative symptoms of schizophrenia
Roche today reports results from a 320 patient phase II proof-of-concept study with it’s investigational glycine transporter-1 ... more

09. November 2009
Invitation to Roche investor science event from ASH 2009 - Conference call on 8 December 2009
more

09. November 2009
Anti-Malignancy Agent Avastin Obtained Approval for Additional Indication of Non-Small Cell Lung Cancer
Please find attached a press release issued by Chugai in Japan more

29. October 2009
First Phase III clinical trial of Roche`s weekly taspoglutide meets primary end-point of change in HbA1c
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus ... more

22. October 2009
Phase III trial underway to investigate infusion-free administration of Herceptin for women with HER2-positive breast cancer
Roche and Halozyme Therapeutics announced today that a new subcutaneous formulation of Herceptin using Halozyme’s Enhanze ... more

19. October 2009
Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
Please find attached a press release issued by Genentech and Biogen Idec in the US with respect to the approval of Rituxan ... more

17. October 2009
ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, ... more

16. October 2009
Anti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody, Avastin Application for Approval of Additional Indication of Breast Cancer
Please find enclosed a press release by Chugai more

15. October 2009
Roche reports further accelerated sales growth in third quarter
Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in ... more

07. October 2009
Reminder: Roche's Third Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... more

05. October 2009
Two Phase III studies of Lucentis show early and sustained improvement in vision in patients with retinal vein occlusion
Genentech, Inc., a wholly-owned member of the Roche Group yesterday announced results from two Phase III studies of Lucentis® ... more

30. September 2009
RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
Roche announced today that it has submitted a filing to the European health authorities (the European Medicines Agency) to ... more

25. September 2009
Roche provides update on early-stage breast cancer study with Avastin
Roche has been informed by the National Cancer Institute and US Eastern Cooperative Oncology Group (ECOG) that they have suspended ... more

24. September 2009
Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer
A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose ... more

24. September 2009
Continuous improvements in animal welfare within Roche Research
Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit ... more

24. September 2009
Anti-Cancer Agent Xeloda and Avastin Obtained Approval for Additional Indication of Colorectal Cancer
Please find enclosed a press release by Chugai more

23. September 2009
Adding Xeloda to standard chemotherapy before surgery helps to eradicate tumours in patients with early breast cancer
Results from the ABCSG 24 trial presented today at the joint 15th ECCO and 34th ESMO 2009 congress, Berlin, Germany showed ... more

23. September 2009
From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases
New data from several studies presented at ECCO 151 and ESMO 342 confirm unique benefits of Avastin (bevacizumab) and Xeloda ... more

23. September 2009
Roche announces results from two early studies which show promise for patients with malignant melanoma
New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor more

23. September 2009
Phase IV lung cancer study confirms the safety and outstanding efficacy benefit of Avastin-based therapy in a 'real world' setting.
Key data from four presentations at the joint ECCO 15 and ESMO 34 congress strongly support the clinical benefit of Avastin ... more

21. September 2009
Reminder: Roche Investor Science Event: Conference Call from ECCO ESMO 2009 - Friday, September 25th, 2009
We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being ... more

18. September 2009
Antineoplastic Agent / Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Tarceva
Application for Approval of Additional Indication of Pancreatic Cancer more

17. September 2009
Study shows MabThera maintenance treatment delays disease progression in patients with incurable lymphoma
Results show patients treated with MabThera as initial and follow-on therapy stay in remission for longer. Roche announced ... more

14. September 2009
Roche's Third Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... more

13. September 2009
Two new studies report increased survival rates in Tamiflu-treated patients with avian flu (H5N1) and severe seasonal flu
53% of patients with H5N1 infection survived when treated with Tamiflu compared with 12% of untreated patients. Rate of death ... more

11. September 2009
Roche Investor Science Event: Conference Call from ECCO ESMO 2009 - Friday, September 25th, 2009
We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being ... more

08. September 2009
Roche announces new Corporate Executive Committee
William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire – Pascal Soriot appointed COO Pharma Division and ... more

03. September 2009
Roche recognised as new Super Sector Leader in Dow Jones Sustainability Index
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been rated as the new Super Sector Leader in Healthcare on the Dow Jones Sustainability ... more

03. September 2009
MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemia
Roche announced today that the European Commission has approved MabThera (rituximab) for use in patients with relapsed or ... more

01. September 2009
Roche receives CE Mark certification for cobas 8000 modular analyzer series
Roche announced today that the CE Mark certification for cobas 8000 modular analyzer series has been granted allowing commercial ... more

31. August 2009
FDA Approves Valcyte (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
Plus new oral solution offers dosing flexibility for pediatric patients. Roche announced today that the U.S. Food and Drug ... more

31. August 2009
Roche and Lonza Announce Opt-in for Singapore Manufacturing Facility
Roche and Lonza announced today that Genentech Singapore Pte. Ltd. (“Genentech Singapore”), a wholly-owned member ... more

18. August 2009
Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a Phase III study of Avastin (bevacizumab) in combination with a range ... more

05. August 2009
Roche Continents takes place for the third time
For the third time, Roche and the Salzburg Festival have invited 100 students to take part in "Roche Continents". ... more

03. August 2009
Avastin approved in US for the most common type of kidney cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon ... more

01. August 2009
Phase III study showed Tarceva helped patients with advanced non-small cell lung cancer live longer when used immediately after initial chemotherapy
Roche today announced that patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva (erlotinib) immediately ... more

31. July 2009
FDA accepts complete response resubmission for ACTEMRA (tocilizumab)
Roche announced today that the U.S. Food & Drug Administration (FDA) has accepted the resubmission for the ACTEMRA (tocilizumab) ... more

30. July 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
Roche announced today that the Phase III study CRUISE showed Lucentis (ranibizumab injection) improved vision in patients ... more

29. July 2009
European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancer
More patients with advanced breast cancer could benefit from Avastin as a result of a broader label allowing Avastin to be ... more

28. July 2009
Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head, Clinical Development Hematology/Oncology
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the appointment of ... more

28. July 2009
Roche and Google.org Start Initiative for Early Discovery of New Diseases
Roche Applied Science and Google.org recently started a joint project to demonstrate the feasibility of developing a multidisciplinary ... more

24. July 2009
MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returns
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation ... more

24. July 2009
Full reconciliation of Chugai interim results into IFRS
Following the publication of Chugai’s official 2009 interim results, Roche offers this investor update which reconciles ... more

23. July 2009
Double-digit increase in sales, operating profit and Core EPS
Integration of Genentech progressing rapidly; full-year outlook raised; Group sales up 2 billion to 24 billion Swiss francs, ... more

22. July 2009
Reminder: Roche's Half Year Results for 2009
Roche will publish its Half Year Results for 2009 prior to the opening of the Swiss Stock Exchange on July 23 at 7.00 CET ... more

22. July 2009
Chugai Files NDA for a Renal Anemia Agent R744
Please find enclosed a press release by Chugai. more

21. July 2009
Roche Diagnostics showcases new technology at Clinical Lab Expo
Roche Diagnostics is featuring a diverse portfolio of solutions designed to help healthcare facilities and reference labs ... more

20. July 2009
Xeloda in combination with oxaliplatin shown to be effective in early colon cancer
Roche announced today results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination ... more

13. July 2009
New data from phase III SATURN study shows Tarceva improves overall survival when used immediately after initial chemotherapy in patients with advanced lung cancer
Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in ... more

02. July 2009
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Roche announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured ... more

01. July 2009
Roche launches novel program to ease Tamiflu access to developing economies
Roche today announced the initiation of the Tamiflu Reserves Program (TRP) for developing economies. The program, which is ... more

26. June 2009
European regulator gives positive opinion for the use of Avastin in combination with docetaxel for the first-line treatment of advanced breast cancer
Physicians will be able to offer patients more Avastin-based treatment options. Patients with advanced (metastatic) breast ... more

26. June 2009
Roche Files MabThera as a First-line Biologic Treatment for Rheumatoid Arthritis in Europe
Roche announced today that it has submitted a combined filing to the European health authorities (the European Medicines Agency) ... more

23. June 2009
Roche's Half Year Results for 2009
Roche will publish its Half Year Results for 2009 prior to the opening of the Swiss Stock Exchange on July 23 at 7.00 CET ... more

11. June 2009
New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis
RA patients with enhanced response identified. New data show for the first time that a course of 2 infusions of MabThera 1000mg ... more

11. June 2009
Reminder: Roche Investor Science Event: Conference call from EULAR 2009
We are pleased to invite you to a Conference Call to discuss new data on our Rheumatoid Arthritis portfolio being presented ... more

11. June 2009
Reminder: Invitation to Roche Accounting Teleconference
We are pleased to invite you to an accounting conference call followed by Q&A on the impact of the Genentech transaction ... more

10. June 2009
New data reinforces long-term efficacy of ACTEMRA in rheumatoid arthritis across all patient population types
Up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the ... more

09. June 2009
Roche to commence phase III trials with innovative treatment designed to lower cardiovascular risk in diabetes patients with recent heart attack
Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 ... more

08. June 2009
Invitation to Roche Accounting Teleconference
We are pleased to invite you to an accounting conference call followed by Q&A on the impact of the Genentech transaction ... more

05. June 2009
Reminder: Roche investor science event from ADA 2009
We kindly invite investors and analysts to participate in a conference call that will be held during the American Diabetes ... more

02. June 2009
IMPACT study shows longer Valcyte treatment provides better protection against cytomegalovirus (CMV) disease
New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) ... more

01. June 2009
Encouraging first data on new targeted treatment for patients with melanoma - the deadliest form of skin cancer
Roche announced today results from a phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for ... more

31. May 2009
Herceptin landmark study (ToGA) reveals unprecedented survival benefit in HER2-positive stomach cancer
Data from the ToGA study presented today at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida ... more

30. May 2009
Phase III study showed patients lived longer without advanced lung cancer progressing when Tarceva was added to Avastin as first-line maintenance therapy
Roche today announced that a Phase III study (ATLAS) showed patients with advanced non-small cell lung cancer (NSCLC) who ... more

30. May 2009
Full results from first Phase III study of Avastin in adjuvant colon cancer announced
Results suggest future trials may hold promise for Avastin as early-stage colon cancer treatment even though C-08 study does ... more

28. May 2009
New form of targeted therapy offers further hope to patients with advanced HER2-positive breast cancer
Final results from a phase II study presented at ASCO show that 25% of women with advanced HER2-positive breast cancer experienced ... more

27. May 2009
Reminder: Roche investor science event from ADA 2009
Phase II data on PPAR co-agonist aleglitazar and overall update on Roche´s diabetes & metabolic diseases pipeline more

26. May 2009
Roche Investor Science Event: Conference call from EULAR 2009
We are pleased to invite you to a Conference Call to discuss new data on our Rheumatoid Arthritis portfolio being presented ... more

25. May 2009
Reminder - Roche Investor Events: ASCO 2009
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products ... more

25. May 2009
Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis
Roche announced today that new two-year data from the LITHE study demonstrate that ACTEMRA (tocilizumab, known as RoACTEMRA ... more

20. May 2009
Roche ASCO planner
Roche and Genentech will present a large number of abstracts on their broad oncology portfolio at the Annual Meeting of American ... more

19. May 2009
Genentech and Biogen Idec submit applications to the FDA for Rituxan for most common type of adult leukemia
Genentech, Inc., wholly owned member of the Roche Group (SWX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) today ... more

19. May 2009
Roche Investor Events: ASCO 2009
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products ... more

18. May 2009
Roche joins forces to innovate toxicity testing and to reduce animal experimentation
Today, Roche opened the Joint Science & Technology Laboratory in Basel, where Roche Pharma scientists are using the innovative ... more

15. May 2009
Avastin plus commonly used chemotherapies improved progression-free survival in advanced breast cancer
Data from RIBBON 1 study provides efficacy and safety information with different types of chemotherapy more

15. May 2009
Roche to present major advances with targeted cancer medicines at ASCO
More than 500 scientific abstracts to be presented across 20 types of cancers. Results could significantly improve the way ... more

11. May 2009
Roche investor science event from ADA 2009
Phase II data on PPAR co-agonist aleglitazar and overall update on Roche's diabetes & metabolic diseases pipeline more

06. May 2009
Important New Treatment Option Approved in US for Patients with the Most Aggressive Form of Brain Cancer
Roche today announced that the US Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) ... more

04. May 2009
Roche Investor Events: ASCO 2009
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products ... more

30. April 2009
Roche responds to WHO move to influenza pandemic alert phase 5
Roche tonight confirms that it has been in contact with the World Health Organization (WHO) following the announcement to ... more

27. April 2009
Ground-breaking combination of all-oral agents demonstrates potential as hepatitis C treatment regimen
Roche (SWX: RO, ROG; OTCQX: RHHBY), InterMune, Inc. (Nasdaq: ITMN) and Pharmasset (Nasdaq: VRUS) announced the first results ... more

22. April 2009
Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpoint
Roche today announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy ... more

16. April 2009
Roche strongly outperforms market in first quarter
Genentech transaction completed, integration proceeding rapidly more

15. April 2009
Reminder: Roche's First Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... more

15. April 2009
Roche Diabetes Care supports "Changing Diabetes in Children"
Roche today announced that it will join forces with Novo Nordisk and the World Diabetes Foundation (WDF) in Novo Nordisk’s ... more

14. April 2009
Roche and Genentech announce organizational and leadership decisions
Following the completion of the Genentech transaction Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) today announced the successful ... more

08. April 2009
Roche and Genentech announce voluntary withdrawal of Raptiva from the U.S. market
Roche and Genentech, Inc. announced today a phased voluntary withdrawal of the psoriasis drug Raptiva (efalizumab) from the ... more

07. April 2009
Presentational changes of Roche's quarterly sales results
As announced earlier, the Roche Group will publish its first quarter sales results on 16 April 2009. To reflect the Pharmaceuticals ... more

02. April 2009
Roche to introduce new LightCycler MRSA Advanced Test in the EU
Roche announced today that its new LightCycler test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) ... more

01. April 2009
FDA ADVISORY COMMITTEE UNANIMOUSLY RECOMMENDS ACCELERATED APPROVAL OF AVASTIN FOR PREVIOUSLY TREATED BRAIN CANCER (GLIOBLASTOMA)
Genentech, Inc. announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... more

31. March 2009
Avastin label updated reflecting confidence in safety profile
The European Medicines Agency (EMEA) has removed a restriction in the product label which prevented the use of Avastin (bevacizumab) ... more

26. March 2009
Roche completes acquisition of Genentech
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech announced today that Roche has completed its acquisition of Genentech ... more

26. March 2009
Roche completes tender offer for Genentech
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed ... more

24. March 2009
RiskMetrics Group Recommends Genentech Shareholders Accept Roche's $95.00 per Share Cash Tender Offer
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that RiskMetrics Group, Inc., a leading provider of risk and corporate ... more

19. March 2009
Roche announces filing of Tarceva in EU as first-line maintenance therapy in advanced non-small cell lung cancer
Today, Roche submitted an extension of the Marketing Authorisation Application to the European Medicines Agency (EMEA) for ... more

18. March 2009
Roche's First Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... more

18. March 2009
Herceptin now shown to significantly prolong the lives of patients with HER2-positive advanced stomach cancer
Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard ... more

12. March 2009
Roche and Genentech reach a friendly agreement to combine the two organizations and create a leader in healthcare innovation
Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE: DNA) announced today that they signed a merger agreement under which Roche ... more

11. March 2009
Herceptin proven to benefit women with HER2 positive early breast cancer - latest results from the HERA study
The Breast International Group (BIG) in collaboration with Roche announced today that women with HER2 positive early breast ... more

10. March 2009
Roche Annual General Meeting: dividend raised by 9 percent
Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. ... more

06. March 2009
Roche increases offer price for Genentech shares to US$ 93 per share and extends offer
Roche (SWX: ROG.VX; RO.S) announced today that it has increased its offer price for all outstanding publicly-held shares of ... more

27. February 2009
Roche announces bond offerings
Roche has successfully undertaken a large offering of notes in U.S. dollars, and is completing another large offering of notes ... more

27. February 2009
MabThera approved in the EU for patients with chronic lymphocytic leukaemia
Roche announced today that the European Commission has approved MabThera (rituximab) in combination with chemotherapy for ... more

16. February 2009
Study proves longer prophylactic therapy with Valcyte increases protection against CMV - the most serious viral infection affecting transplant patients
Roche announced today that a Phase III study investigating the efficacy and safety of extended preventative therapy ('prophylaxis') ... more

16. February 2009
For the first time, doctors can predict which hepatitis B patients have the highest chance to achieve treatment success with Pegasys
New data presented today showed that, for the first time, doctors can predict which hepatitis B patients treated with Pegasys ... more

09. February 2009
Roche commences tender offer for Genentech for US$86.50 per share in cash
Roche announced today that it is commencing a cash tender offer for all outstanding publicly-held shares of Genentech for ... more

04. February 2009
Strong operating results for Roche in 2008
Double-digit sales growth – Core Earnings per share at constant exchange rates above 2007 level – Dividend increase ... more

03. February 2009
Reminder: Roche's Full Year Results for 2008
Roche will publish its Full Year Results for 2008 prior to the opening of the Swiss Stock Exchange on February 4 at 7.00 CET ... more

03. February 2009
Avastin and Tarceva in combination significantly improves the time patients with advanced lung cancer can live without their disease worsening
Roche today announced interim results from a phase III study (ATLAS) in patients with advanced non small cell lung cancer ... more

30. January 2009
Roche intends to commence tender offer to acquire all shares of Genentech for US$ 86.50 per share in cash
Roche announced today that it intends to commence a cash tender offer for all outstanding publicly-held shares of Genentech ... more

28. January 2009
Roche delighted about pool extension
Roche’s Board of Directors and Corporate Executive Committee is delighted about the extension of the shareholders’ ... more

28. January 2009
MabThera filed in the EU for treatment of relapsed or refractory chronic lymphocytic leukaemia
Roche today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) ... more

23. January 2009
MabThera receives positive opinion in Europe for first-line treatment for chronic lymphocytic leukaemia
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation ... more

21. January 2009
Reminder: Roche's Full Year Results for 2008
Roche will publish its Full Year Results for 2008 prior to the opening of the Swiss Stock Exchange on February 4 at 7.00 ... more

21. January 2009
RoACTEMRA approved in Europe to treat patients suffering from Rheumatoid Arthritis
Roche today announced that the European Commission has approved RoACTEMRA (tocilizumab, known as Actemra outside of the EU), ... more

05. January 2009
Roche's Full Year Results for 2008
4 February – 8.00 CET – Morning Telephone Conference 4 February - 15.00 GMT - Presentation in London (16.00 CET) 6 ... more

05. January 2009
Roche Purchases Shares in Tender Offer for Memory Pharmaceuticals Corp.
Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that its wholly-owned subsidiary 900 North Point Acquisition Corporation ... more